LDS/Medical Tests/Amyotrophic Lateral Sclerosis Gene Mutation Panel, NGS

Amyotrophic Lateral Sclerosis Gene Mutation Panel, NGS

Amyotrophic Lateral Sclerosis (ALS) is a progressive, fatal neurodegenerative disease involving motor neurons in the brain and spinal cord. The disease is caused by the gradual degeneration and death of both upper motor neurons (UMN) and lower motor neurons (LMN). The common initial symptoms are muscle weakness or stiffness and as disease progresses all muscles under voluntary control are affected impacting the patient's ability to speak, eat, move, and breathe. Most people with ALS die from respiratory failure, usually within 3 to 5 years of their diagnosis. Most ALS cases (90 percent or more) are considered sporadic or not associated with the familiar inheritance and 10% are inherited as familial ALS (FALS). Sporadic ALS is considered to be a complex disease, in which genetic and environmental factors combine to increase the risk of developing the condition. Whereas the familial form is mostly related to specific gene mutations. At least 15 genes have been associated with the various types of familial ALS.

The Amyotrophic Lateral Sclerosis Gene Mutation Panel tests for most common genes mutation associated with ALS and FALS. Depends on the lab offering the test, the panel should include the common Amyotrophic Lateral Sclerosis -associated genes: ALS2, ANG, ATL1, ATXN2, C9orf72, CHGB, CHCHD10, CHMP2B, DCTN1, FIG4, FUS, HNRNPA1, OPTN, PFN1, PRPH, SETX, SIGMAR1, SOD1, TARDBP, UBQLN2, VAPB, VCP.

  • As an aid in diagnosis of Amyotrophic Lateral Sclerosis
  • To determine subtype, and assess risk for family members
One or more pathogenic mutation(s) detected supports a diagnosis of Amyotrophic Lateral Sclerosis.

No mutations detected (Negative for mutation analyzed) Genetic cause of ALS not identified. This reduces, but does not exclude, the likelihood of Familial Amyotrophic Lateral Sclerosis.

Next Generation Sequencing (NGS); Target sequencing and or Exome Sequencing.

Whole blood, EDTA (lavender top tube).

Stability

  • Ambient: 7 days
  • Refrigerated: 7-14 days
  • Frozen: unacceptable
Creatine Kinase (CK), Liver panel, Acetylcholine Receptor (AChR) Antibody, Muscle biopsy, Spinal tab, Cerebrospinal Fluid Microscopic Evaluation, Myelin Associated Glycoprotein (MAG) Antibody.
2-3 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login